Ixazomib Citrate

伊沙佐米

Report date: 2023/05/10 10:37:58
NME

Base Information

Drug NameIxazomib Citrate
Drug Alias Name埃沙佐米Ixazomibum艾沙佐米艾莎佐米阿西佐米 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProteasome inhibitors
TargetsProteasome
Therapy Area/IndicationsSolid tumoursGraft vs Host DiseaseAmyloidosis +[39] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryUnited States
Original Approved Date2015/11/20
Country/TerritoryCzechiaBelgiumCanada +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals International, IncTakeda Pharmaceuticals USA IncHaupt Pharma Amareg Gmbh +[14] 
Inactive CompaniesDana-Farber Cancer InstituteWashington University School Of MedicineOhsu Knight Cancer Institute +[9] 
Active IndicationsAmyloidosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive +[15] 
Inactive IndicationsSolid tumoursGraft vs Host DiseaseMyelodysplastic Syndromes +[24] 

Other Information

ATC CodeL01XG03
Related LinksWikipediaDrugBankKEGG